Oncology – Breast
Cohort Study | Potential negative survival impact of PPI and palbociclib co-administration in breast cancer patients
8 Aug, 2023 | 13:07h | UTC
RCT | Mammography screening with AI reduces workload by 44.3% without loss in detection efficacy
4 Aug, 2023 | 12:13h | UTCArtificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study – The Lancet Oncology (link to abstract – $ for full-text)
News Release: First randomized trial finds AI-supported mammography screening is safe and almost halves radiologist workload – Lancet
Commentaries:
Large Mammography Study Shows Significant Benefits with AI-Aided Screening – Diagnostic Imaging
Systematic Review | Interstitial lung disease incidence at 11.7% in metastatic breast cancer patients using trastuzumab deruxtecan
3 Aug, 2023 | 13:36h | UTC
Review | Atypical hyperplasia of the breast: Clinical cases and management strategies
3 Aug, 2023 | 13:07h | UTC
Systematic Review | Post-mastectomy RT likely lowers recurrence and improves survival in early breast cancer with 1-3 positive nodes
25 Jul, 2023 | 13:34h | UTC
RCT | Total breast reconstruction with autologous fat transfer using an expansion device vs implants in patients with breast cancer
28 Jun, 2023 | 13:12h | UTCEffect of Total Breast Reconstruction With Autologous Fat Transfer Using an Expansion Device vs Implants on Quality of Life Among Patients With Breast Cancer: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
See also: Visual Abstract
Author Interview: Effect of Breast Reconstruction With Autologous Fat Transfer vs Implants on Quality of Life – JAMA
M-A | Effectiveness of physical therapy in axillary web syndrome after breast cancer
27 Jun, 2023 | 13:28h | UTC
Review | Treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm
26 Jun, 2023 | 00:27h | UTC
Cohort Study | Steady reduction in breast cancer mortality from 1993-2015 in England
22 Jun, 2023 | 14:58h | UTCInvited Commentary: Risk of breast cancer death after a diagnosis of early invasive breast cancer – The BMJ
Commentary on Twitter
NEW research finds that most women diagnosed with early breast cancer can expect to become long term cancer survivors https://t.co/TaYqRJD6Lu pic.twitter.com/V15bLdmI2H
— The BMJ (@bmj_latest) June 14, 2023
Updated Guidance | Diagnosis and treatment of Early and locally advanced breast cancer
22 Jun, 2023 | 14:52h | UTC
RCT | Increased detection of metastases via PET-CT alters treatment path in locally advanced breast cancer
16 Jun, 2023 | 14:02h | UTCImpact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT | Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer
15 Jun, 2023 | 15:04h | UTC
ASCO Guideline Update | Human epidermal growth factor receptor 2 testing in breast cancer
14 Jun, 2023 | 14:15h | UTC
RCT | Capivasertib–fulvestrant improves PFS vs. fulvestrant alone in HR+ advanced breast cancer
13 Jun, 2023 | 13:54h | UTCCapivasertib in Hormone Receptor–Positive Advanced Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Video: Capivasertib in Advanced Breast Cancer | NEJM
Commentary: Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer – MedicalXpress
Commentary on Twitter
Among persons with breast cancer previously treated with hormonal therapy, the AKT pathway inhibitor capivasertib when added to fulvestrant significantly prolonged progression-free survival as compared with fulvestrant alone. Full results of CAPItello-291: https://t.co/ZCBHkG305b
— NEJM (@NEJM) May 31, 2023
RCT | Adding dalpiciclib to standard letrozole or anastrozole treatment outperforms placebo in HR+, HER2- advanced breast cancer
7 Jun, 2023 | 13:44h | UTCDalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Dalpiciclib Combo Improves PFS Vs Placebo in HER2– Advanced Breast Cancer – Cancer Network
Review | Advances in systemic therapies for triple negative breast cancer
5 Jun, 2023 | 13:36h | UTCAdvances in systemic therapies for triple negative breast cancer – The BMJ
USPSTF Draft Statement recommends biennial screening mammography for women ages 40 to 74 years
22 May, 2023 | 13:56h | UTCBreast Cancer: Screening – U.S. Preventive Services Task Force
Critical perspectives on the statement:
Earlier screening for breast cancer: Benefits and harms – Lown Institute
Why more mammograms aren’t the solution to breast cancer – Vox
ASCO Guideline Update | ESR1 mutation testing for HR+/HER2- metastatic breast cancer therapy
22 May, 2023 | 13:27h | UTC
Cohort Study | Following lifestyle recommendations linked to lower recurrence in high-risk breast cancer
15 May, 2023 | 12:48h | UTCCommentary: Adherence to healthy lifestyle found to cut breast cancer recurrence, mortality – HealthDay
Commentary on Twitter
Adherence to the @AmericanCancer and the @aicrtweets lifestyle recommendations before and after high-risk breast cancer treatment was associated with a 37% reduced risk of disease recurrence and a 58% reduction in mortality. https://t.co/sy6b8CGgr1
— JAMA Network Open (@JAMANetworkOpen) May 4, 2023
Uncertainties and controversies in axillary management of patients with breast cancer
11 May, 2023 | 11:53h | UTC
Single-arm study | Halting endocrine therapy for pregnancy not linked to increased breast cancer events vs. a control cohort
10 May, 2023 | 16:01h | UTCInterrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In women with previous breast cancer who temporarily discontinued adjuvant endocrine therapy to attempt pregnancy, the frequency of breast cancer events was below the prespecified safety threshold and similar to that in controls (POSITIVE trial). https://t.co/zM3f4SbgjE
— NEJM (@NEJM) May 3, 2023
New ACR breast cancer screening guidelines call for earlier and more-intensive screening for high-risk women
9 May, 2023 | 14:50h | UTCGuideline: Breast Cancer Screening for Women at Higher-than-Average Risk: Updated Recommendations from the ACR
Effects of intraoperative fluorescence guidance for breast cancer lumpectomy surgery
9 May, 2023 | 14:48h | UTCIntraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery – NEJM Evidence
News Release: Study finds fluorescent guide can help detect tumor left behind after breast cancer surgery – Mass General Brigham
RCT | Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor–positive breast cancer
9 May, 2023 | 14:32h | UTCPostoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
M-A | Quality of life after risk-reducing surgery for breast and ovarian cancer prevention
9 May, 2023 | 14:21h | UTC